checkpointtx.comOverview Checkpoint Therapeutics

Home About Us Management Team Board of Directors Pipeline CK-101 EGFR Inhibitor CK-301 Anti-PD-L1 CK-103 BET Inhibitor CK-302 Anti-GITR Anti-CAIX Publications Business Development Investors & Media Overview Stock Information Press Releases Corporate Presentation SEC Filings & Financials SEC Filings Events Management Team Corporate Governance Analyst Coverage FAQs Information Request Contact Us Checkpoint Therapeutics, Inc., a company founded by Fortress Biotech, is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. read more >   -- Press Releases 5.06.20 Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights 4.21.20 Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab 3.11.20 Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights Lead Programs CK-301 Anti-PD-L1 CK-101 EGFR Inhibitor Program 2 Gansevoort Street 9th Floor New York, NY 10014 781-652-4500 info@checkpointtx.com © Copyright 2018 Checkpoint Therapeutics, Inc. Privacy Policy Disclaimer Sitemap...